Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BETTER2: Chemo +/- Bevacizumab in Pancreatic NETs
NCT03351296Phase 2Active, not recruiting
- Sponsor
- Gustave Roussy
- Start
- Jun 2018
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in Pancreatic neuroendocrine tumor (PanNET), sponsored by Gustave Roussy. Started Jun 2018; status: active, not recruiting.
02
Drugs
bevacizumab
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT03351296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03351296.